Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Labcyte and Deerac Fluidics Combine Forces to Enhance Low Volume Liquid Handling

Published: Wednesday, January 30, 2008
Last Updated: Wednesday, January 30, 2008
Bookmark and Share
Labcyte and Allegro Technologies Limited have reached agreement on the terms for combination of the two companies.

Labcyte Inc. and Allegro Technologies Limited, which conducts business as Deerac Fluidics, announced that they have reached agreement on the terms for combination of the two companies. Completion of the transaction requires shareholder approval and is expected within one month.

As pharmaceutical companies, genomic service providers, and other life science research organizations desire to perform larger numbers of assays within fixed budgets, there is a strong drive to reduce the volume of each assay in order to reduce cost and minimize waste.

According to both companies, although products from both Labcyte and Deerac address the growing market of low-volume liquid handling, each company utilizes a unique technology and they operate in different volume ranges. Products from Labcyte and Deerac are used for different applications. They may also be used together when one component of an assay is added in the low nanoliter range and others are added in larger amounts.

The Deerac products are based on a patented feed-back controlled system which effective in the 50 nanoliter to 20 microliter range. This technology was conceived at Trinity College Dublin, and its development was supported by grants from Enterprise Ireland.

The Labcyte Echo ® liquid handlers use acoustic energy to transfer 2.5 nanoliter droplets and are most useful in the 2.5 to 200 nanoliter range.

“At Labcyte, we evaluated a wide variety of low-volume liquid handlers and found the Deerac Latitude™ and Equator™ to have the best precision in the 50 nanoliter range. We also found that the speed and flexibility of the Latitude could double the throughput of our new POD™ 810 plate assembler for assay plate preparation. The two teams have also conducted several joint seminars on low-volume assays and our people work well together,” said Dr. Elaine J. Heron, Chief Executive Officer of Labcyte. “It became clear that it made sense to combine the two companies.”

“Having research and manufacturing groups in Dublin gives us a solid base from which to support our growing business in Europe,” continued Dr. Heron. “Dublin offers a vibrant research community with business-friendly policies. The innovative atmosphere created by Trinity College Dublin makes location of our European operations close by especially attractive.”

“We are excited to become part of the business that has brought acoustic droplet ejection from a concept to a mainstream product used by most pharmaceutical companies,” said Dr. Jurgen Osing, the Managing Director of Deerac Fluidics, “and we are anxious to use our expertise in genomics to expand the applications of Labcyte Echo systems. This is also an opportunity for providing more local support for the Latitude and Equator products.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos